BODY & DOSE
DEAD

Serial Number

88313657

Owner

MOLESCI & MATESCI INC

Attorney

Francis John Ciaramella

Filing Date

Feb 24, 2019

Add to watchlist:

No watchlists yet
View on USPTO

BODY & DOSE Trademark

Serial Number: 88313657

BODY & DOSE is a trademark filed by MOLESCI & MATESCI INC on February 24, 2019. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

MOLESCI & MATESCI INC (3 trademarks)

39 Jeffcoat Dr
Etobicoke M9W3B6 , CA

Entity Type: 03

Trademark Details

Filing Date

February 24, 2019

Registration Date

Not Registered

Goods & Services

Phytotherapeutics, herbal medicines and pharmaceutical preparations for cellular health such as chemopreventive, preventing memory Loss and Alzheimer's disease, carbohydrate and glucose burning therapy to prevent diabetics, control body lean mass, and as LDL lowering agents; pharmaceutical preparations to treat the symptoms or disease such as respiratory and central nervous system stimulants, anti-inflammatories, pain management, digestive disorders, sleep disorders, anti-nausea and vomiting, Parkinson's disease, post-traumatic stress disorder (PTSD), Epilepsy, Autism, Anti-diabetics, and for controlling and stabilizing blood pressure; pharmaceutical agents for boosting brain activity; pharmaceutical preparations for treating dementia and Alzheimer's; Nutritional pharmaceutical preparations, herbal medicines and phyto-drugs for maintaining good cellular health, slowing down the aging process, providing vital energy for growth, anti-aging, cardiovascular health and the prevention of cancer, namely, promoting cellular growth, enhancing the immunity system, helping to lower low-density lipoprotein (LDL) cholesterol and raise high-density lipoprotein (HDL) cholesterol, promoting healthy blood sugar, controlling blood sugar for pre-diabetes, improving and maintaining kidney and liver health, improving sexual desire and enhancing the libido, preventing cardiovascular disease, maintaining cellular health; pharmaceutical preparations, namely, lipid lowering agents, agents for the prevention of colon, breast and prostate cancer; and nutraceuticals dosages, namely, solid edibles in the form of tablets. Capsules, gummies, powder blends, and cakes for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; semi-solid edibles in the form of gummies, chewables, and lozenges for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; pharmaceutical preparations in the nature of liquid ingestible in the form of syrups, sprays, sublingual sprays, and nasal sprays for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; pharmaceutical preparations in the nature of alcoholic and non-alcoholic drinks in the form of emulsions, suspensions, decotions, elixirs, tinctures for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; pharmaceutical preparations in the nature of infusion inhalers in the form of liquid mist and vape pens for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; pharmaceutical preparations in the nature of dermal and transdermal creams, gels, lotions, patches, and serums for the treatment of cancer, diabetes, and infectious, cardio-vascular, gastro-intestinal and neurologic diseases; Dermatological pharmaceutical preparations for skin health, such as for the treatment of skin conditions, namely, dermatitis, eczema, psoriasis and for the treatment of acne; medicated cosmeceutical products for anti-aging, anti-wrinkle, moisturizers and skin conditioning agents in the form of dermal or transdermal creams, gels, lotions, patches, and serum

Non-medicated cosmeceuticals products for anti-aging, anti-wrinkle, moisturizers and skin conditioning agents in the form of dermal or transdermal creams, gels, lotions, patches, and serum

Retail store services featuring products for health and personal care. Retail stores providing, namely, organic clothes, organic foods, functional foods, cosmeceuticals, Skin and body care products, nutritional pharmaceuticals and herbal medicinal products

Health care services for treating dementia and Alzheimers; providing wellness services, namely, weight loss and health consulting offered at a wellness center; medical and clinics services, namely, opioid withdrawal or replacement symptoms therapies; medical services, namely, nicotine replacement therapies; medical services, namely, providing treatment for patients with Arthritis, Rheumatoid Arthritis, Chronic Pain, Migraines, Muscle Spasms, Sleep Disorders, Insomnia, Alzheimer's, Glaucoma, Muscular Dystrophy, Back and Neck Problems, Spinal Cord Injury/Disease Epilepsy. Parkinson's Disease, Hepatitis C, Mobility Disorders, Multiple Sclerosis, Nausea, Colitis, Crohn's Disease, Irritable Bowel Syndrome (IBS), Lupus, Autism, Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Back Pain, Depression, Post Traumatic Stress Disorder (PTSD), Fibromyalgia, Anorexia Nervosa, Bulimia Nervosa, Nausea from Cancer Treatment, Human Immunodeficiency Virus (HIV), Acquired Immune Deficiency Syndrome (AIDS)

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 4, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 4, 2025 ABN2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 17, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 17, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 17, 2024 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 11, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 11, 2024 GNSL
SUSPENSION LETTER WRITTEN
Mar 11, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 7, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 6, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 6, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 6, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 6, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 27, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 27, 2023 GNSL
SUSPENSION LETTER WRITTEN
Mar 27, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2023 CRFA
ASSIGNED TO LIE
Mar 24, 2023 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 17, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 20, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 20, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 20, 2022 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 7, 2022 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 3, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 3, 2022 GNSL
SUSPENSION LETTER WRITTEN
Mar 3, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2022 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 24, 2022 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 25, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 25, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 25, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 22, 2021 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 13, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 13, 2021 GNSL
SUSPENSION LETTER WRITTEN
Apr 13, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 13, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 13, 2021 CRFA
ASSIGNED TO LIE
Apr 13, 2021 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 7, 2021 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 7, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 7, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 7, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 7, 2020 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 6, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 6, 2020 GNSL
SUSPENSION LETTER WRITTEN
Apr 6, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 3, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 3, 2020 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 2, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 9, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 9, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 9, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 9, 2020 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 8, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 8, 2019 GNSL
SUSPENSION LETTER WRITTEN
Jul 8, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 27, 2019 CRFA
ASSIGNED TO LIE
Jun 27, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 21, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
May 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
May 9, 2019 CNRT
ASSIGNED TO EXAMINER
May 4, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2019 NWOS